不同降压药物治疗原发性高血压的药物经济学研究进展  

Pharmacoeconomics Research Progress of Different Antihypertensive Drugs in the Treatment of Essential Hypertension

作　　者：冯琦 赵程龙 刘敬宇 关利新[1] FENG Qi;ZHAO Cheng-Long;LIU Jing-Yu;GUAN Li-Xin(School of Pharmacy,Mudanjiang Medical University,Mudanjiang 1570ll,China)

机构地区：[1]牡丹江医学院药学院,黑龙江牡丹江157011

出　　处：《中国药物经济学》2025年第2期104-107,共4页China Journal of Pharmaceutical Economics

基　　金：国家自然科学基金委员会资助项目(81973317)。

摘　　要：高血压是发生心血管事件的主要危险因素,患者需长期服用降压药物。长期用药价格较昂贵,在保证降压疗效的同时,需选择成本-效益最优的降压药物进行治疗。本研究对近年来我国不同降压药物治疗原发性高血压患者的药物经济学评价结果进行综述,旨在为患者提供最合理的降压选择。Hypertension is a major risk factor for cardiovascular events,and patients need to take long-term antihypertensive drugs.The price of long-term medication is expensive.While ensuring the antihypertensive effect,it is necessary to select the antihypertensive drugs with the best cost-effectiveness for treatment.This study reviewed the pharmacoeconomic evaluation results of different antihypertensive drugs in the treatment of patients with essential hypertension in China in recent years,aiming to provide the most reasonable antihypertensive choice for patients.

关 键 词：原发性高血压 降压药物 药物经济学 

分 类 号：R544.1[医药卫生—心血管疾病] R956[医药卫生—内科学]